About Us

Malaysian Genomics Resource Centre Berhad (Bursa Malaysia, ACE, MGRC, 0155) is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, Malaysian Genomics has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions, which include:

Genome Sequencing and Bioinformatics Analysis Services
Genome sequencing involves converting biological information contained in DNA into computer data, which can then be studied using bioinformatics analysis. We offer related contract research services for customers across the commercial life sciences, including healthcare, agriculture, plantation, and industrial biotechnology.

Genetic Screening and Molecular Biology Services
We develop and supply tests used to identify genetic risks associated with diseases (cancer, heart diseases, etc.), health traits (nutrition, fitness, etc.), and adverse reactions to prescription medications. We also provide laboratory services for COVID-19 and other testing.

Immunotherapy and Cell Therapy Products
We provide cell engineering and production services for various clinical therapies including Chimeric Antigen Receptor (CAR) T-cell immunotherapy for certain blood and solid cancers. We also produce and supply cells for non-clinical use, e.g., for anti-ageing and wellness markets.

Other Services
Product Distribution: We market and distribute laboratory equipment and consumables, and medical consumables.
Product Development: We provide R&D or OEM for bespoke genetic tests.